{"entity":{"id":"nct05304481","kind":"trial","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","aka":[],"tldr":"A phase 2 trial of ATL administration in hepatocellular carcinoma, run by Lukas Biomedical Inc., now recruiting.","summary":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT05304481 by Lukas Biomedical Inc., with 95 participants planned, started 2022-05-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: ATL administration.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05304481","url":"https://clinicaltrials.gov/study/NCT05304481"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05304481","phase":"2","setting":"A Phase II Study to Evaluate the Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (HCC) Patients After Curative Treatment","sponsor":"Lukas Biomedical Inc.","participation":[{"nct":"NCT05304481","source":"https://clinicaltrials.gov/study/NCT05304481","fetchedAt":"2026-10-07T16:53:39.725Z","studySha256":"dba59018ca75780546f42d654786e0e70e7e93aa0d50148bc8f6573219b081ed","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-01","leadSponsor":"Lukas Biomedical Inc.","collaboratorCount":1,"minimumAge":"20 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":95,"enrolmentType":"ESTIMATED","siteCount":14,"recruitingSiteCount":13,"countries":["Taiwan"]}],"started":"2022-05-14","startedType":"actual","enrolled":95,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05304481/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}